Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Deferred Income Tax
The difference between tax expense recognized and tax actually paid in cash during the period.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Deferred Income Tax · Q1 FY2026 · quarter ended Mar 2026
Deferred income tax outflow grows to $0
Q1 FY2026 deferred income tax was $0, compared with $0 a year earlier. Trailing-twelve-month deferred income tax was $0.
What to watch
Whether quarterly deferred income tax holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Deferred Income Tax history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Income Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
Deferred Income Tax vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's LTM Mar 2026 deferred income tax of $0 is the largest of the 10 companies compared; the peer median is $0.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $0 | — | — | — | |
TACOUBerto Acquisition Corp. Unit | FY2025 | $0 | — | — | — |
| FY2025 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
TACHTitan Acquisition Corp. | LTM Mar 2026 | $0 | — | — | — |
OYSEOyster Enterprises II Acquisition Corp | FY2025 | $0 | — | — | — |
| LTM Mar 2026 | $0 | — | — | — | |
| FY2025 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| FY2025 | $0 | — | — | — | |
| Peer median (excluding DMAA) | $0 | — | — | — | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (479) | 3.97M |
| Depreciation & Amortization | 0 | 0 |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 132 | 138.85K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 0 | 144.9K |
| Other Working Capital | 132 | (6.05K) |
| Other Non-Cash Items | (171.92K) | (4.65M) |
| Operating Cash Flow | (295) | (539.19K) |
| Capital Expenditures | 5 | 0 |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | 0 | 0 |
| Sales of Investments | 0 | 0 |
| Other Investing Activities | 0 | (231.15M) |
| Investing Cash Flow | 0 | (231.15M) |
| Debt Repayment | 502.21K | (900K) |
| Common Stock Issued | (328.6K) | 232.05M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 1 | 543.97K |
| Financing Cash Flow | 173.62K | 231.69M |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | 1.35K | 4.79K |
| Free Cash Flow | (295) | (539.19K) |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.